Dominic B. Zanaboni MD , Christopher T. Sower MD , Sunkyung Yu MS , Ray Lowery BA , Jennifer C. Romano MD, MS , Jeffrey D. Zampi MD
{"title":"Practice variation using the hybrid stage I procedure in congenital heart disease: Results from a national survey","authors":"Dominic B. Zanaboni MD , Christopher T. Sower MD , Sunkyung Yu MS , Ray Lowery BA , Jennifer C. Romano MD, MS , Jeffrey D. Zampi MD","doi":"10.1016/j.xjon.2024.07.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Hybrid stage I palliation has been used in many clinical scenarios including initial palliation in single ventricle heart disease, a bridge to biventricular repair, a bridge to transplant, and as a destination therapy. There is considerable hybrid stage I palliation practice variation, which we aimed to better understand in this study.</div></div><div><h3>Methods</h3><div>Survey-based assessment of practice variation related to hybrid stage I palliation was sent to congenital heart centers across the United States and Canada.</div></div><div><h3>Results</h3><div>Of the 106 centers surveyed, responses were received from 54 centers (50.9%). Of respondents, 45 centers perform hybrid stage I palliation. Centers most commonly (97.7%) perform hybrid stage I palliation on “high-risk” patients with single ventricle heart disease. Regarding the technical aspects of hybrid stage I palliation, most centers (95.3%) accomplish restrictive pulmonary blood flow using pulmonary artery bands and primarily use changes in oxygen saturation (34.1%) to identify appropriate restriction. Ductal stents are most often used (67.4%) to maintain ductal patency. Only 10 centers (23.3%) routinely enlarge the atrial septal defect. Indications for atrial septal defect intervention varied widely. Most centers (71.9%) discharge patients home to follow with a formal “interstage” program.</div></div><div><h3>Conclusions</h3><div>There is significant variation in practice patterns for hybrid stage I palliation indications, technical aspects, and postoperative care. Therefore, generalizability of single-center studies on outcomes after hybrid stage I palliation is limited. Future multicenter studies are needed to best delineate which patients benefit most from hybrid stage I palliation and to further define optimal approaches to caring for these patients.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"21 ","pages":"Pages 248-256"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTCVS open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666273624002341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
Hybrid stage I palliation has been used in many clinical scenarios including initial palliation in single ventricle heart disease, a bridge to biventricular repair, a bridge to transplant, and as a destination therapy. There is considerable hybrid stage I palliation practice variation, which we aimed to better understand in this study.
Methods
Survey-based assessment of practice variation related to hybrid stage I palliation was sent to congenital heart centers across the United States and Canada.
Results
Of the 106 centers surveyed, responses were received from 54 centers (50.9%). Of respondents, 45 centers perform hybrid stage I palliation. Centers most commonly (97.7%) perform hybrid stage I palliation on “high-risk” patients with single ventricle heart disease. Regarding the technical aspects of hybrid stage I palliation, most centers (95.3%) accomplish restrictive pulmonary blood flow using pulmonary artery bands and primarily use changes in oxygen saturation (34.1%) to identify appropriate restriction. Ductal stents are most often used (67.4%) to maintain ductal patency. Only 10 centers (23.3%) routinely enlarge the atrial septal defect. Indications for atrial septal defect intervention varied widely. Most centers (71.9%) discharge patients home to follow with a formal “interstage” program.
Conclusions
There is significant variation in practice patterns for hybrid stage I palliation indications, technical aspects, and postoperative care. Therefore, generalizability of single-center studies on outcomes after hybrid stage I palliation is limited. Future multicenter studies are needed to best delineate which patients benefit most from hybrid stage I palliation and to further define optimal approaches to caring for these patients.
目的杂交I期姑息治疗已被用于多种临床情况,包括单心室心脏病的初始姑息治疗、双心室修复的桥梁、移植的桥梁以及作为终末治疗。混合型 I 期姑息治疗在实践中存在相当大的差异,我们希望在本研究中更好地了解这一点。方法对美国和加拿大的先天性心脏病中心进行了混合型 I 期姑息治疗相关实践差异的调查评估。在答复者中,有 45 家中心实施了 I 期混合姑息术。这些中心最常(97.7%)对患有单心室心脏病的 "高危 "患者实施混合I期姑息术。关于杂交 I 期姑息术的技术方面,大多数中心(95.3%)使用肺动脉带完成限制性肺血流,并主要使用氧饱和度的变化(34.1%)来确定适当的限制。最常用的方法是使用导管支架(67.4%)来保持导管通畅。只有 10 个中心(23.3%)常规扩大房间隔缺损。房间隔缺损介入治疗的适应症差异很大。大多数中心(71.9%)让患者出院回家,并通过正式的 "阶段间 "计划进行后续治疗。因此,关于杂交I期姑息术后疗效的单中心研究的推广性是有限的。未来需要开展多中心研究,以确定哪些患者从杂交I期姑息术中获益最多,并进一步确定护理这些患者的最佳方法。